Carbogen Amcis appoints Stephan Fritschi as CEO
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
Arth by Emcure is a specialized range of supplements designed to address the unique health and wellness needs of women, enabling them to lead healthier and happier lives across all stages
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
This certification will open new markets for the Kwality Pharma
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Subscribe To Our Newsletter & Stay Updated